Veillonella dispar

(aka Veillonella alcalescens subsp. dispar)

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Veillonella dispar, (aka Veillonella alcalescens subsp. dispar), is a Gram-negative, non-spore-forming, strictly anaerobic, non-motile, bacterium. It has been detected in at least 20 gut microbiome compilation studies or metastudies. The DNA G+C content is 38-40%. Veillonella dispar is a common gut coloniser. (Rogosa1965a; Carlier2011Bergey)



  • This organism has been recovered from oral flora, clinical sources (endocarditis and infections) and human faeces. The risk classification (www.baua.de) for this organism is 1, i.e., low risk of infection and spread (notes: opportunistic in immunocompromised patients). It is an opportunistic pathogen. A possible gut commensal. Robust growth can have negative consequences for gut health.
    • GENERAL CHARACTERISTICS (Rogosa1965a); (Carlier2011Bergey);
    Character Response
  • Active enzymes:
  • naphthol-ASBI-P;
    • SPECIAL FEATURES (Carlier2011Bergey);
    Character Response
  • ✗
  • Metabolites not produced:
  • indole;
  • ±
  • Nitrate:
  • strain dependent
    • RESPONSE TO ANTIBIOTICS (Carlier2011Bergey); (Goldstein2018a); (Goldstein2013a); (Goldstein2013b); (Tyrrell2012); (Citron2012a); (Goldstein2006); (Goldstein2006c); (Citron2003); (Goldstein2003a); (Goldstein2000a); (Goldstein1999b);
    Class Active Resistant
  • Penicillins:
  • amoxicillin-clavulanic acid; ampicillin; ampicillin-sulbactam; imipenem; meropenem; ticarcillin-clavulanic acid;
  • Cephalosporins:
  • cefmetazole; cefotaxime; cefotetan; cefoxitin;
  • ceftazidime;
  • Macrolides:
  • azithromycin; telithromycin;
  • clarithromycin; fidaxomicin; roxithromycin;
  • Tetracyclines:
  • tigecycline;
  • Quinolines:
  • ciprofloxacin; gatifloxacin; levofloxacin;
  • Polypep/ketides:
  • bacitracin;
  • Heterocycles:
  • chloramphenicol; metronidazole;
  • trimethoprim-sulfamethoxazole;
  • Vancomycins:
  • vancomycin; teicoplanin;
  • Miscellaneous antibiotics:
  • clindamycin; linezolid; telithromycin;
  • daptomycin;

  • Dal Bello, F., & Hertel, C. (2006). Oral cavity as natural reservoir for intestinal lactobacilli. Systematic and Applied Microbiology, 29(1), 69–76.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Firmicutes Class:  Negativicutes Order:  Veillonellales Family:  Veillonellaceae Genus:  Veillonella Alt. name:  Veillonella alcalescens subsp. dispar Gram stain:  neg O2 Relation.:  strictly anaerobic Spore:  No spore Motility:  Sessile
    Health:   Negative
    Source:  oral flora, clinical sources (endocarditis and infections) and human faeces
    DNA G+C(%):  38-40
    		Aesculin:  neg Urea:  neg Gelatin:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg Glucose:  neg Mannose:  neg Rhamnose:  neg Xylose:  neg Cellubiose:  neg Lactose:  neg Maltose:  neg Melezitose:  neg Sucrose:  neg Trehalose:  neg Glycerol:  neg Mannitol:  neg Sorbitol:  neg Salicin:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  neg Urease:  neg Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  neg β-Glucosidase:  neg β-Glucuronidase:  neg ArgDH:  neg GluDC:  neg AlanineAA:  neg GluGluAA:  neg GlyAA:  neg LeuAA:  neg LeuGlyAA:  neg PyrrolidAA:  neg AlkalineP:  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Augmentin:  S(MIC50): 0.5, MIC90: 2, RNG: (≤0.015–>4)
    ampicillin:  S(MIC50): 2, MIC90: 4, RNG: (0.125–8)
    amp-sulb:  S(MIC50): 0.5, MIC90: 1, RNG: (0.06–2)
    penicillin_G:  Var(MIC50): 1, MIC90: 8, RNG: (0.06-8)
    piper-taz:  Var(MIC50): 0.25, MIC90: >128, RNG: (0.06->128)
    tica-clav:  S(MIC50): 0.25, MIC90: 4, RNG: (0.06->128)
    imipenem:  S(MIC50): 0.5, MIC90: 1, RNG: (0.06–1)
    meropenem:  S(MIC50): 0.03, MIC90: 0.03, RNG: (0.03–0.25)
    cefalexin:  Var(MIC50): 2, MIC90: 8, RNG: (0.25-16)
    cefmetazole:  S(0.25)
    cefotaxime:  S(MIC50): 4, MIC90: 8, RNG: (0.06–8)
    cefotetan:  SensRNG: (0.12-2)
    cefoxitin:  S(MIC50): 4, MIC90: 4, RNG: (0.25–8)
    ceftazidime:  R(MIC50): 8, MIC90: 32, RNG: (2–32)
    cefuroxime:  Var(MIC50): 4, MIC90: 16, RNG: (0.25–16)
    azithromycin:  S(MIC50): 1, MIC90: 2, RNG: (0.125->32)
    erythromycin:  Var(MIC50): 4, MIC90: 8, RNG: (0.5->32)
    fidaxomicin:  R(MIC50): 128, MIC90: 256, RNG: (16–512)
    clarithromycin:  R(MIC50): 16, MIC90: >32, RNG: (1–>32)
    roxithromycin:  R(MIC50): >32, MIC90: >32, RNG: (0.5–>32)
    telithromycin:  S(MIC50): 2, MIC90: 4, RNG: (0.06–32)
    linezolid:  S(MIC50): 0.5, MIC90: 1, RNG: (0.25–2)
    ciprofloxacin:  S(MIC50): ≤0.5, MIC90: 4, RNG: (≤0.5->8)
    gatifloxacin:  S(MIC50): 0.125, MIC90: 2, RNG: (0.062)
    gemifloxacin:  Var(MIC50): 1, MIC90: 8, RNG: (0.03–>8)
    levofloxacin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (≤0.06-8)
    moxifloxacin:  Var(MIC50): 0.5, MIC90: 4, RNG: (0.06–>32)
    trovafloxacin:  Var(MIC50): 0.25, MIC90: >8, RNG: (0.125–>8)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  Var(MIC50): 2, MIC90: 16, RNG: (0.5–>16)
    tetracycline:  Var(MIC50): 2, MIC90: 16, RNG: (0.5-32)
    tigecycline:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.06–0.5)
    teicoplanin:  R(MIC50): >256, MIC90: >256, RNG: (64–>256)
    vancomycin:  R(MIC50): >64, MIC90: >64, RNG: (64–>64)
    bacitracin:  R(MIC50): >256, MIC90: >256, RNG: (16–>256)
    chloramphenicol:  S(MIC50): 2, MIC90: 8, RNG: (0.25–32)
    metronidazole:  S(MIC50): 2, MIC90: 4, RNG: (0.125-4)
    SXT:  R(8-256)
    clindamycin:  S(MIC50): 0.06, MIC90: 0.125, RNG: (≤0.03->32)
    daptomycin:  R(MIC50): >32, MIC90: >32, RNG: (>32)

    References

    SPECIFIC REFERENCES FOR VEILLONELLA DISPAR
  • Mays1982 - Taxonomy of the Genus Veillonella Prevot.
  • Rogosa1965a - The Genus Veillonella IV. Serological Groupings, and Genus and Species Emendations.
  • Carlier2011Bergey - Bergey's manual of systematic bacteriology. Vol. 3, The Firmicutes. Family Veillonellaceae, Genus I. Veillonella
  • Bajer2017 - Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis
  • Giongo2011 - Toward defining the autoimmune microbiome for type 1 diabetes
  • Hoffman2014 - Escherichia coli dysbiosis correlates with gastrointestinal dysfunction in children with cystic fibrosis
  • Huang2019 - Analysis of microbiota in elderly patients with Acute Cerebral Infarction
  • Jackson2016 - Signatures of early frailty in the gut microbiota
  • Li2012 - Molecular-phylogenetic characterization of the microbiota in ulcerated and non-ulcerated regions in the patients with Crohn's disease
  • Li2019b - Disordered intestinal microbes are associated with the activity of Systemic Lupus Erythematosus
  • Liu2019a - The intestinal microbiota associated with cardiac valve calcification differs from that of coronary artery disease
  • PerezBrocal2015 - Metagenomic Analysis of Crohn's Disease Patients Identifies Changes in the Virome and Microbiome Related to Disease Status and Therapy, and Detects Potential Interactions and Biomarkers
  • Qin2014 - Alterations of the human gut microbiome in liver cirrhosis
  • Wang2019b - Alterations in the human gut microbiome associated with Helicobacter pylori infection
  • Zheng2020a - Specific gut microbiome signature predicts the early-stage lung cancer
  • Zhu2020 - Metagenome-wide association of gut microbiome features for schizophrenia
  • Laue2020 - Prospective associations of the infant gut microbiome and microbial function with social behaviors related to autism at age 3 years
  • Goldstein2018a - Comparative In Vitro Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains.
  • Goldstein2013a - Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates.
  • Goldstein2013b - Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms.
  • Tyrrell2012 - In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.
  • Citron2012a - Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
  • Goldstein2006 - In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
  • Goldstein2006c - Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.
  • Citron2003 - In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
  • Goldstein2003a - In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
  • Goldstein2000a - Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.
  • Goldstein1999b - Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR VEILLONELLA DISPAR
  • Aujoulat2014 - Temporal dynamics of the very premature infant gut dominant microbiota.
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Chen2020 - Structural and Functional Characterization of the Gut Microbiota in Elderly Women With Migraine
  • Chen2020a - Featured Gut Microbiomes Associated With the Progression of Chronic Hepatitis B Disease
  • DalBello2006 - Oral cavity as natural reservoir for intestinal lactobacilli.
  • Dubinkina2017 - Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease
  • Favier2002 - Molecular monitoring of succession of bacterial communities in human neonates.
  • Forster2019 - A human gut bacterial genome and culture collection for improved metagenomic analyses.
  • Hu2019 - The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients
  • Jeong2021 - The effect of taxonomic classification by full-length 16S rRNA sequencing with a synthetic long-read technology
  • Jie2017 - The gut microbiome in atherosclerotic cardiovascular disease
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • McLaughlin2010 - The bacteriology of pouchitis: a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing.
  • New2022 - Collective effects of human genomic variation on microbiome function.
  • PerezBrocal2015 - Metagenomic Analysis of Crohn's Disease Patients Identifies Changes in the Virome and Microbiome Related to Disease Status and Therapy, and Detects Potential Interactions and Biomarkers
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Walker2011 - High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease.
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • Zou2019 - 1,520 reference genomes from cultivated human gut bacteria enable functional microbiome analyses.
  • ...............................
    • GENERAL REFERENCES FOR VEILLONELLA DISPAR
  • Ludwig2009 - Revised road map to the phylum Firmicutes.
    • Added: April 08, 2021